Canada’s Competition Bureau approved a deal between GlaxoSmithKline PLC and Novartis AG, saying in a statement that U.S. authorities had already said the transaction could go ahead. The two firms agreed last April to the deal that includes GSK buying Novartis’ vaccines business, Novartis purchasing GSK’s cancer drugs, and the two groups merging in consumer healthcare.